July 5, 2016 / 11:57 AM / in a year

BRIEF-Intellipharmaceutics says Rexista results indicate no food effect

July 5 (Reuters) - Intellipharmaceutics International Inc :

* Intellipharmaceutics reports update on Rexista XR: FDA grants waiver of NDA filing fee, and topline pharmacokinetics results indicate no food effect

* FDA has completed its review of our request and has granted a waiver of $1,187,100 application fee for Rexista XR

* Food effect study showed that Rexista XR can be administered with or without a meal

* Company plans to file NDA for Rexista XR in August of 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below